abarelix
Selected indexed studies
- Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827. (Drugs R D, 2003) [PMID:12757402]
- Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. (Expert Opin Pharmacother, 2004) [PMID:15461552]
- Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. (Future Oncol, 2006) [PMID:17155895]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Abarelix: abarelix-depot-F, abarelix-depot-M, abarelix-L, PPI 149, R 3827. (2003) pubmed
- Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. (2004) pubmed
- Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. (2006) pubmed
- Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. (2009) pubmed
- Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer. (2004) pubmed
- Technology evaluation: Abarelix, Praecis pharmaceuticals. (2000) pubmed
- Abarelix (plenaxis). (2004) pubmed
- A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. (2001) pubmed
- Abarelix (Plenaxis) for advanced prostate cancer. (2004) pubmed
- Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75. (2004) pubmed